JP2017536085A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536085A5 JP2017536085A5 JP2017515243A JP2017515243A JP2017536085A5 JP 2017536085 A5 JP2017536085 A5 JP 2017536085A5 JP 2017515243 A JP2017515243 A JP 2017515243A JP 2017515243 A JP2017515243 A JP 2017515243A JP 2017536085 A5 JP2017536085 A5 JP 2017536085A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- genes
- gene
- expression
- protein encoded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185673 | 2014-09-19 | ||
| EP14185673.2 | 2014-09-19 | ||
| PCT/EP2015/071524 WO2016042164A1 (en) | 2014-09-19 | 2015-09-18 | A method of predicting risk of recurrence of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536085A JP2017536085A (ja) | 2017-12-07 |
| JP2017536085A5 true JP2017536085A5 (enExample) | 2018-11-08 |
| JP6730983B2 JP6730983B2 (ja) | 2020-07-29 |
Family
ID=51589137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515243A Active JP6730983B2 (ja) | 2014-09-19 | 2015-09-18 | 癌の再発リスクを予測する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10557175B2 (enExample) |
| EP (1) | EP3194621B1 (enExample) |
| JP (1) | JP6730983B2 (enExample) |
| AU (1) | AU2015316711B2 (enExample) |
| CA (1) | CA2961725C (enExample) |
| ES (1) | ES2753625T3 (enExample) |
| IL (1) | IL251141B (enExample) |
| NZ (1) | NZ730124A (enExample) |
| WO (1) | WO2016042164A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ730124A (en) * | 2014-09-19 | 2023-05-26 | Univ College Dublin Nat Univ Ireland Dublin | A method of predicting risk of recurrence of cancer |
| JP7131773B2 (ja) | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ホルモン受容体に関連する転写活性の標的尺度 |
| CN106039312B (zh) * | 2016-05-25 | 2019-07-23 | 中山大学肿瘤防治中心 | Znf367基因在制备治疗乳腺癌药物、诊断及预后评估试剂中的应用 |
| GB201709417D0 (en) * | 2017-06-14 | 2017-07-26 | Inst Of Cancer Research: Royal Cancer Hospital | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer |
| USD875753S1 (en) * | 2018-03-06 | 2020-02-18 | Ventana Medical Systems, Inc. | Display screen or portion thereof with graphical user interface for biological slide scanning |
| WO2021072280A1 (en) * | 2019-10-09 | 2021-04-15 | The University Of North Carolina At Chapel Hill | Dna copy number alterations (cnas) to determine cancer phenotypes |
| EP4253567A1 (en) * | 2022-03-31 | 2023-10-04 | OncoAssure Limited | A method of predicting risk of an aggressive or recurrent cancer |
| WO2025239278A1 (ja) * | 2024-05-16 | 2025-11-20 | 公益財団法人がん研究会 | リンパ管侵襲またはリンパ節転移の可能性を判定するための検査方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050365T2 (hu) | 2003-06-24 | 2022-09-28 | Genomic Health Inc | Rákkiújulás valószínûségének elõrejelzése |
| US20080275652A1 (en) | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| US7914988B1 (en) | 2006-03-31 | 2011-03-29 | Illumina, Inc. | Gene expression profiles to predict relapse of prostate cancer |
| US9605319B2 (en) * | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
| WO2014066796A2 (en) * | 2012-10-25 | 2014-05-01 | Myriad Genetics, Inc. | Breast cancer prognosis signatures |
| CA2901761A1 (en) | 2013-02-21 | 2014-08-28 | Myriad Genetics, Inc. | Gene signatures for lung cancer prognosis and therapy selection |
| NZ730124A (en) * | 2014-09-19 | 2023-05-26 | Univ College Dublin Nat Univ Ireland Dublin | A method of predicting risk of recurrence of cancer |
-
2015
- 2015-09-18 NZ NZ730124A patent/NZ730124A/en unknown
- 2015-09-18 ES ES15778623T patent/ES2753625T3/es active Active
- 2015-09-18 US US15/511,890 patent/US10557175B2/en active Active
- 2015-09-18 EP EP15778623.7A patent/EP3194621B1/en active Active
- 2015-09-18 JP JP2017515243A patent/JP6730983B2/ja active Active
- 2015-09-18 WO PCT/EP2015/071524 patent/WO2016042164A1/en not_active Ceased
- 2015-09-18 CA CA2961725A patent/CA2961725C/en active Active
- 2015-09-18 AU AU2015316711A patent/AU2015316711B2/en active Active
-
2017
- 2017-03-14 IL IL251141A patent/IL251141B/en active IP Right Grant
-
2019
- 2019-12-20 US US16/722,041 patent/US20200157643A1/en not_active Abandoned
-
2022
- 2022-12-15 US US18/066,693 patent/US20240002947A1/en not_active Abandoned
-
2023
- 2023-08-07 US US18/366,436 patent/US12545961B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536085A5 (enExample) | ||
| Mao et al. | A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma | |
| Lv et al. | miRNA expression patterns in chemoresistant breast cancer tissues | |
| Ko et al. | MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy | |
| Chan et al. | MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer | |
| Wang et al. | High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro | |
| Petrillo et al. | Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors | |
| Fagone et al. | Identification of novel chemotherapeutic strategies for metastatic uveal melanoma | |
| Kim et al. | Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing | |
| Shen et al. | microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation | |
| WO2019075251A3 (en) | Cancer score for assessment and response prediction from biological fluids | |
| Li et al. | Circulating microRNA-137 is a potential biomarker for human glioblastoma. | |
| Xu et al. | hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR | |
| UA110790C2 (uk) | Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні | |
| Jung et al. | EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI | |
| Ahmad et al. | HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to regulate colonic epithelial cell differentiation | |
| Liu et al. | Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23. | |
| He et al. | A prognostic 11 long noncoding RNA expression signature for breast invasive carcinoma | |
| US20200294622A1 (en) | Subtyping of TNBC And Methods | |
| Kravets et al. | The study of prognostic value of microRNAs (miR-10b and-155) and CDKN2A/P16INK4A in oral squamous cell carcinoma | |
| Penrod et al. | Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivity | |
| Severson et al. | Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients | |
| JP2024543138A5 (enExample) | ||
| US20220233563A1 (en) | Methods of Treatments Based Upon Anthracycline Responsiveness | |
| He et al. | Identification of genes associated with lung adenocarcinoma prognosis |